Kamada Ltd. (KMDA)
NASDAQ: KMDAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
KMDA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $446.85M
- P/E (TTM)
- 20.37
- Forward P/E
- 13.34
- EPS (TTM)
- $0.38
- Dividend yield
- 7.24% ($0.56)
- Ex-dividend date
- Nov 19, 2026
- 52-week range
- 6.63 – 9.35
- Day range
- 7.72 – 7.97
- Volume / Avg
- 84.30K / 121.87K
- Beta
- —
- Shares outstanding
- 57.73M
52-week range
KMDA stock today
Kamada (KMDA) closed at $7.74 on Nov 20, down 1.15% (-$0.09), versus the S&P 500's 3.70% decline. Shares are 17.2% below their 52-week high of $9.35, set on Feb 25, 2026 and 16.7% above the 52-week low of $6.63, in the middle of the past year's range. KMDA is up 9.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 14.7%.
Kamada trades at 20.4x its trailing twelve-month earnings per share of $0.38. Its forward P/E of 13.3x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Kamada pays an annual dividend of $0.56 per share, a 7.24% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Kamada
Company profileKamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Amir London
- Headquarters
- Rehovot
- Employees
- 462
- IPO year
- 2013
- Website
- kamada.com
Financial highlights
Full financialsIn fiscal 2025, Kamada generated $180.5 million in revenue, up 12.1% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $20.2 million (+39.7% year over year), for a net margin of 11.2% versus a median of 5.8% in the prior 5 years. Gross margin was 42.3% (down from 43.5%) and operating margin 14.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $180.46M | $160.95M | $142.52M | $129.34M | $103.64M |
| Growth | +12.12% | +12.93% | +10.19% | +24.79% | -22.22% |
| Net income | $20.20M | $14.46M | $8.28M | $-2.32M | $-2.23M |
| EPS (diluted) | $0.35 | $0.25 | $0.15 | $-0.05 | $-0.05 |
Analyst forecast
ForecastConsensus (3 analysts)
strong_buy
Avg. price target
$13.75+77.65%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $0.09 vs $0.13
- Surprise
- -30.77%
Dividends
Dividend history- Annual dividend
- $0.56
- Dividend yield
- 7.24%
- Last payment
- $0.14
- Ex-dividend date
- Nov 19, 2026
- Pay date
- Dec 9, 2026
KMDA news
All KMDA news- Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to ShareholdersGlobeNewswire
- Kamada (KMDA) Q3 2026 Earnings Call TranscriptNasdaq
- Kamada Reports Record-High First Nine Months 2026 Financial Results; Increases 2026 Annual Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2027GlobeNewswire
- Kamada Declares Cash Dividend of $0.14 Per Share; The Company Continues its Record-High YearGlobeNewswire
- Kamada to Announce Third Quarter and Nine Months Ended September 30, 2026, Financial Results on November 9, 2026GlobeNewswire
- Kamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026GlobeNewswire
Kamada peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| STTKShattuck Labs Inc. | 4.46 | -1.98% | $454.22M | vs KMDA |
| ASMBAssembly Biosciences Inc. | 22.19 | -1.38% | $454.39M | vs KMDA |
| NGNENeurogene Inc. | 22.15 | -3.40% | $458.53M | vs KMDA |
| DMACDiaMedica Therapeutics Inc. | 8.25 | +2.87% | $445.15M | vs KMDA |
| AMRNAmarin Corporation plc | 10.57 | -6.13% | $444.39M | vs KMDA |
| GYREGyre Therapeutics Inc. | 4.21 | -6.86% | $460.79M | vs KMDA |
| CTMXCytomX Therapeutics Inc. | 2.03 | -0.98% | $442.55M | vs KMDA |
| BLSMBlossomHill Therapeutics Inc. | 14.51 | +0.69% | $461.20M | vs KMDA |
Indexes, lists and sector
Kamada stock FAQ
What is Kamada's stock price today?
KMDA last traded at $7.74 as of Nov 20, 4:00 PM EST, down 1.15% on the day. Prices are delayed at least 15 minutes.
Does Kamada pay a dividend?
Yes. Kamada pays $0.56 per share annually, a 7.24% yield. The most recent dividend of $0.14 had an ex-dividend date of Nov 19, 2026.
What is KMDA's P/E ratio?
KMDA trades at a trailing P/E ratio of 20.37 and a forward P/E of 13.34.
Who is Kamada's CEO?
Mr. Amir London is the chief executive officer of Kamada Ltd., which has about 462 employees.
What is the KMDA 52-week high?
The 52-week high for KMDA is $9.35 and the 52-week low is $6.63. The stock is currently 17.2% below its high.